Genome Insight
Genome Insight, operating under the brand Inocras, is a precision medicine company focused on whole genome sequencing (WGS) for cancer and rare diseases.
Profile
Provides whole genome sequencing tests and analysis for cancer and rare disease diagnosis.
Genome Insight, operating under the brand Inocras, is a precision medicine company focused on whole genome sequencing (WGS) for cancer and rare diseases. Founded by scientists and physicians, the company aims to address the limitations of conventional targeted sequencing panels by providing comprehensive genomic analysis. Headquartered in San Diego with R&D offices in Seoul and Daejeon, South Korea, Genome Insight has positioned itself as a player in the growing field of genomic diagnostics.
The company's collaboration with Ultima Genomics, announced in April 2023, seeks to combine Ultima's low-cost sequencing technology with Genome Insight's bioinformatics platform to make WGS more accessible for cancer patients. Genome Insight's approach claims to identify 25% more complex mutations in cancer patients compared to standard tests, according to their website. Their CAP/CLIA-certified tests promise a two-week turnaround time, targeting both clinical and research applications. While specific financials and headcount aren't publicly disclosed, the company's partnership strategy and focus on cost reduction suggest a growth trajectory in the competitive genomic testing market.
Who buys this
- Oncologists and healthcare providers seeking comprehensive cancer genomic profiles
- Researchers in academic and pharmaceutical settings studying cancer biology
- Patients with rare genetic disorders seeking diagnostic clarity
- Clinical trial operators needing genomic screening for participant selection
Strengths and what to watch
Strengths
- CAP/CLIA-certified whole genome tests with claimed >99% sensitivity for variant detection
- Strategic partnership with Ultima Genomics for cost-reduced sequencing infrastructure
- Dual presence in US and South Korea with specialized R&D capabilities
Watch for
- Dependence on Ultima Genomics' unproven UG 100 platform for cost structure
- Competition from established players like GeneDx expanding into whole genome analysis
- Limited public data on test adoption rates or clinical impact studies
Key Information
- Founded
- 2019
- Headquarters
- San Diego
Frequently Asked Questions
What does Genome Insight do?
Genome Insight provides whole genome sequencing tests for cancer and rare disease diagnosis. Operating as Inocras, this precision medicine company offers comprehensive genomic analysis, claiming to identify 25% more complex mutations than standard tests. Their CAP/CLIA-certified tests deliver results within two weeks for clinical and research use.
How accurate are Genome Insight's genetic tests?
Genome Insight's whole genome sequencing tests are CAP/CLIA-certified with claimed sensitivity exceeding 99% for variant detection. Their approach identifies more complex mutations compared to conventional methods, particularly in cancer patients. The tests are designed for both clinical diagnostics and research applications.
What makes Genome Insight different from other genetic testing companies?
Genome Insight focuses exclusively on whole genome sequencing rather than targeted panels, providing broader genomic analysis. Their partnership with Ultima Genomics aims to reduce sequencing costs, while their dual US-Korea R&D presence offers specialized capabilities in cancer and rare disease genomics.
Who uses Genome Insight's genetic testing services?
Genome Insight serves oncologists seeking comprehensive cancer profiles, researchers studying cancer biology, patients with rare genetic disorders, and clinical trial operators needing genomic screening. Their tests are used for both diagnostic purposes in healthcare settings and research applications in academic and pharmaceutical environments.
How does Genome Insight's partnership with Ultima Genomics work?
Genome Insight collaborates with Ultima Genomics to combine Ultima's low-cost sequencing technology with Genome Insight's bioinformatics platform. Announced in April 2023, this partnership aims to make whole genome sequencing more accessible for cancer patients while maintaining clinical-grade accuracy.
How long does it take to get results from Genome Insight's tests?
Genome Insight promises a two-week turnaround time for their whole genome sequencing results. Their CAP/CLIA-certified process maintains clinical standards while providing comprehensive genomic data for both cancer and rare disease diagnosis, faster than many conventional genomic testing methods.
Sources
- www.prnewswire.com — Partnership with Ultima Genomics and company mission
- genomeinsight.net — Product offerings and clinical claims
- ir.genedx.com — Competitive landscape context
- ir.genedx.com — Industry growth benchmarks